Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019937 | 1.00 | KIF11 (0.38) | KIF11HRH3GRIN2BHTR7RORC | |
| SCHEMBL4026853 | 1.00 | KIF11 (0.38) | KIF11HRH3GRIN2BHTR7RORC | |
| SCHEMBL4020347 | 0.88 | KIF11 (0.37) | KIF11GRIN2BRORCABCB1 | |
| SCHEMBL4024526 | 0.88 | KIF11 (0.37) | KIF11GRIN2BRORCABCB1 | |
| SCHEMBL4020344 | 0.88 | KIF11 (0.37) | KIF11GRIN2BRORCABCB1 | |
| SCHEMBL4780097 | 0.87 | KIF11 (0.41) | KIF11HRH3RORC | |
| SCHEMBL4778087 | 0.85 | KIF11 (0.47) | KIF11HRH3GRIN2B | |
| SCHEMBL4021213 | 0.85 | GRIN2B (0.38) | KIF11GRIN2BRORCABCB1 | |
| SCHEMBL4022415 | 0.85 | GRIN2B (0.38) | KIF11GRIN2BRORCABCB1 | |
| SCHEMBL4021208 | 0.85 | GRIN2B (0.38) | KIF11GRIN2BRORCABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | KIF11 3745/4885HRH3 1935/4885GRIN2B 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.